ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio0.79
Current Ratio10.65
Quick Ratio8.88
Price-To-Earnings
Trailing P/E Ratio-3.45
Forward P/E Ratio-4.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales12.52
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book6.91
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-119.34%
Return on Equity-89.78%
Return on Assets-29.51%
Miscellaneous
Employees295
Outstanding Shares46,350,000
Market Cap$300.80 million
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) posted its earnings results on Friday, August, 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.03. The biotechnology company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
5 Wall Street analysts have issued 12 month target prices for ADMA Biologics' stock. Their predictions range from $5.00 to $13.00. On average, they expect ADMA Biologics' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 54.5% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Cellectis (CLLS), Autolus Therapeutics (AUTL), Coherus Biosciences (CHRS), Adaptimmune Therapeutics (ADAP), Avrobio (AVRO), Acorda Therapeutics (ACOR), BAVARIAN NORDIC/S (BVNRY), Heska (HSKA), BioCryst Pharmaceuticals (BCRX), Nightstar Therapeutics (NITE), Fate Therapeutics (FATE), Scholar Rock (SRRK), Mesoblast (MESO), Vericel (VCEL) and Voyager Therapeutics (VYGR).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Has ADMA Biologics been receiving favorable news coverage?
Media coverage about ADMA stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a daily sentiment score of 0.18 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for ADMA Biologics.
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.14%), 683 Capital Management LLC (1.91%), Stonepine Capital Management LLC (1.84%), Millennium Management LLC (0.51%), Northern Trust Corp (0.45%) and Ardsley Advisory Partners (0.18%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which institutional investors are selling ADMA Biologics stock?
Which institutional investors are buying ADMA Biologics stock?
ADMA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Stonepine Capital Management LLC, Northern Trust Corp, 683 Capital Management LLC, Ardsley Advisory Partners, Private Advisor Group LLC, Bank of New York Mellon Corp and Bank of New York Mellon Corp. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $6.15.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $300.80 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
